AGI-134: a fully synthetic α-Gal glycolipid that converts tumors into in situ autologous vaccines, induces anti-tumor immunity and is synergistic with an anti-PD-1 antibody in mouse melanoma models

AGI-134: a fully synthetic α-Gal glycolipid that converts tumors into in situ autologous vaccines, induces anti-tumor immunity and is synergistic with an anti-PD-1 antibody in mouse melanoma models

Abstract Background Treatments that generate T cell-mediated immunity to a patient’s unique neoantigens are the current holy grail of cancer immunotherapy. In particular, treatments that do not require cumbersome and individualized ex vivo processing or manufacturing processes are especially sought...

Full description

Bibliographic Details
Main Authors: Stephen M. Shaw, Jenny Middleton, Kim Wigglesworth, Amber Charlemagne, Oliver Schulz, Melanie S. Glossop, Giles F. Whalen, Robert Old, Mike Westby, Chris Pickford, Rinat Tabakman, Irit Carmi-Levy, Abi Vainstein, Ella Sorani, Arik A. Zur, Sascha A. Kristian
Format: Article
Language:English
Published: BMC 2019-12-01
Series:Cancer Cell International
Subjects:
Immunotherapy
alpha-Gal
anti-Gal
Melanoma
anti-PD-1
Checkpoint inhibition
Online Access:https://doi.org/10.1186/s12935-019-1059-8

Internet

https://doi.org/10.1186/s12935-019-1059-8

Similar Items